GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 215 filers reported holding GENMAB A/S in Q1 2023. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,877,963 | -59.6% | 114,523 | -51.9% | 0.01% | -54.5% |
| Q1 2024 | $7,117,264 | -13.1% | 237,956 | -7.5% | 0.01% | -31.2% |
| Q4 2023 | $8,186,573 | +78.5% | 257,116 | +97.8% | 0.02% | +33.3% |
| Q3 2023 | $4,585,347 | -47.4% | 130,007 | -43.3% | 0.01% | -62.5% |
| Q2 2023 | $8,721,356 | -15.5% | 229,449 | -16.1% | 0.03% | -27.3% |
| Q1 2023 | $10,323,697 | -37.4% | 273,403 | -29.7% | 0.04% | -50.0% |
| Q4 2022 | $16,489,253 | +1865.3% | 389,081 | +1577.2% | 0.09% | +1157.1% |
| Q1 2022 | $839,000 | -46.0% | 23,198 | -40.9% | 0.01% | -41.7% |
| Q4 2021 | $1,554,000 | +142.1% | 39,284 | +167.2% | 0.01% | +50.0% |
| Q3 2021 | $642,000 | -32.6% | 14,701 | -36.9% | 0.01% | -27.3% |
| Q2 2021 | $952,000 | -22.9% | 23,315 | -23.3% | 0.01% | -38.9% |
| Q4 2020 | $1,235,000 | +88.3% | 30,383 | +69.5% | 0.02% | +100.0% |
| Q3 2020 | $656,000 | – | 17,924 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 214,848 | $6,980,000 | 2.38% |
| Cutter & CO Brokerage, Inc. | 119,956 | $3,897,000 | 1.33% |
| Hardman Johnston Global Advisors LLC | 933,449 | $30,328,000 | 1.29% |
| Connective Portfolio Management, LLC | 18,000 | $585,000 | 1.00% |
| Capricorn Fund Managers Ltd | 148,411 | $4,822,000 | 0.88% |
| TORRAY INVESTMENT PARTNERS LLC | 131,708 | $4,279,000 | 0.82% |
| First Light Asset Management, LLC | 160,885 | $5,227,000 | 0.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,857 | $57,189,000 | 0.60% |
| Yorktown Management & Research Co Inc | 10,100 | $328,000 | 0.42% |
| Integrated Investment Consultants, LLC | 18,550 | $602,000 | 0.22% |